Reports Oncocyte’s cash, cash equivalents, and restricted cash balance at the end of the second quarter was approximately $11.0 M , up $3.7 million sequentially. This balance includes proceeds from our capital raised in April as well as $1.7 million in restricted cash. flows from operations reflected $1.4 million in bonus and retention payments made to employees in the second quarter, mostly as part of our annual compensation cycle
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCX:
- Oncocyte to Announce Second Quarter 2024 Financial Results on August 8
- OncoCyte files $100M mixed securities shelf
- OncoCyte’s (OCX) Stock Rises With New Diagnostic Product and Promising Partnership.
- OncoCyte Announces Andrea James as New CFO and Principal Officer
- Oncocyte Appoints Andrea James as Chief Financial Officer